Organisation paid for research Program year 2024 Source: CMS Open Payments

Emmaus Research Center Inc

Neither a doctor nor a teaching hospital

Research payments

$1,722,459

129 payments

Through program year 2024, Emmaus Research Center Inc is reported as receiving $1,722,459 in research payments, across 129 payments.

By program year

6 rows

Year	Kind	Amount	Payments
2024	Research	$102,565	6
2023	Research	$286,922	22
2022	Research	$877,468	28
2021	Research	$288,848	5
2020	Research	$70,334	33
2019	Research	$96,323	35

Breakdown

Who paid Research payments · program years 2019–2024

Moderna TX, Inc. $1,540,722 60 payments
GlaxoSmithKline, LLC. $151,468 48 payments
Pfizer Inc. $30,269 21 payments

Studies the money was for Research payments · program years 2019–2024

A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health $1,359,752 49 payments
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled, Age De-escalation, Dose-escalation Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Children 6 months to <12 years of age. $180,970 11 payments
RSV Ped-002 $91,462 28 payments
A Phase 1/2, Randomized, Observer-Blind, Controlled, Multi-Center, Dos $23,280 7 payments
Study name not reported $15,080 1 payment
Menb Rec 2Nd Gen-023 (V72_57) $14,618 8 payments
A Phase 2 Randomized Openlabel Trial to Evaluate the Safety and Immunogenicity of A Multivalent Pneumococcal Conjugate Vaccine Given With Or Separately From 13Valent Pneumococcal Conjugate Vaccine in Healthy Infants $12,611 12 payments
A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Pf04965842 Monotherapy Administered to Adult Patients With Moderatetosevere Atopic Dermatitis $10,013 5 payments
An Openlabel Extension Study to Assess the Longterm Safety and Efficacy of Pf04965842 in Adult Patients With Moderatetosevere Atopic Dermatitis $7,645 4 payments
Rota-081 $3,572 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.